Acutaas Chemicals Quarterly Results for Trading Insights
In Mar 2026, Acutaas Chemicals (ACUTAAS) reported revenue ₹444 Cr and net profit ₹134 Cr — revenue +41.4% YoY. For annual financials, live price and key ratios, visit Acutaas Chemicals share price chart.
ACUTAAS Quarterly Results — Revenue, Profit & EPS Highlights
Acutaas Chemicals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with ACUTAAS fundamental valuation to assess whether the stock is under or overvalued.
- Revenue of ₹444 Cr in Mar 2026 (+40.5% vs Sept 2025, +41.4% vs Mar 2025)
- Net Profit of ₹134 Cr in Mar 2026 (+86.1% vs Sept 2025, +112.7% vs Mar 2025)
- EBITDA of ₹195 Cr in Mar 2026 (+85.7% vs Sept 2025)
- Operating Margin of 42.0% in Mar 2026 (+11.0pp vs Sept 2025)
- Earnings Per Share of ₹16.09 in Mar 2026 (+82.4% vs Sept 2025)
Acutaas Chemicals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ACUTAAS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 444 | 316 | 314 | 223 | 398 | 40.5% | 41.4% |
| Net Profit (₹ Cr) | 134 | 72 | 63 | 44 | 106 | - | - |
| EBITDA (₹ Cr) | 195 | 105 | 91 | 67 | 155 | - | - |
| EPS (₹) | 16.09 | 8.82 | 7.80 | 5.41 | 13.19 | - | - |
| Operating Margin (%) | 42.0% | 31.0% | 28.0% | 25.0% | 38.0% | - | - |
ACUTAAS Share Price Trend — 1-Year Movement Across Quarterly Results
Acutaas Chemicals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore ACUTAAS price movement history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ACUTAAS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Acutaas Chemicals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1874.4 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹180,186.80 Cr | 6753.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.6 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4504.4 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 391.3 |
|
Cipla
Mar 2026 |
₹116,150.78 Cr | 1437.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,873.98 Cr | 1328.4 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 501.3 |
All amounts in ₹ Crores